Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder March 5, 2026 7:30 AM ESTCompany ParticipantsMichael Cola - ...

In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized ...

Helus Pharma (HELP) stock falls as the company posts mid-stage trial data for HLP004, a psychedelic-based therapy for generalized anxiety disorder. Read more here.

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

CLEVELAND — Researchers narrowed down what appears to be the correct dosage during a first ever rigorous clinical trial examining LSD as a treatment for generalized anxiety disorder, with results ...

The latest announcement is out from Cybin ( (HELP) ).

Helus Pharma HELP shares are down on Thursday following the announcement of topline results from a Phase 2 signal detection study for HLP004, a potential treatment for generalized anxiety disorder ...

In a world of constant connectivity and mounting pressures, generalized anxiety disorder (GAD) has emerged as a significant mental health challenge affecting millions. Recent studies show that anxiety ...

News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news ...

If you have anxiety, know that you are not alone. Anxiety disorders are the most common form of mental illness in the United States. Anxiety disorders include, but are not limited to, post traumatic ...

There’s a surprising common thread in the anxious brain—and it may have to do with what’s on your plate.